LUT-014
As of the edition of 20 October 2026, LUT-014 is a small molecule: in active development; acts on BRAF.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2021
- Kind
- Small molecule
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Injuries; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BRAF | Serine/threonine-protein kinase B-raf | P15056 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Lutris Pharma | Lead sponsor of trials | 2019 to now |